Eli Lilly has secured FDA approval for Foundayo, a groundbreaking oral GLP-1 weight-loss pill, bolstering its competitive stance against Novo Nordisk's Wegovy. The approval is anticipated to reshape the obesity drug market, with revenue projections reaching $15 billion by 2029. In a parallel strategic move, Lilly plans to acquire Centessa Pharmaceuticals for $7.8 billion, further diversifying into the lucrative sleep medicine sector.
“$LLY +0.7%: Enters Insilico drug discovery collab worth $2.75bln”
“イーライリリー、センテッサ78億ドルで買収へ－睡眠障害薬を強化 - Bloomberg”
“Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions.”
“as Eli Lilly threatens with a rival pill”
“Eli Lilly & Co.’s weight-loss pill won US approval”
“Eli Lilly’s Zepbound is helping to solve one of the most intractable health challenges of our time: Obesity.”
“Now, the drugmaker hopes to crack another significant public health problem: Sleep disorders.”
“FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market”
“FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market”
“Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more”
“Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison”
